KarisBio, Inc.

KarisBio, Inc. is a clinical-stage biotech company developing regenerative cell therapies for cardiovascular disease. According to BIO International Convention materials, its iPSC-derived endothelial cell therapy is in Phase I trials for peripheral artery disease (PAD) and is described as the world’s first clinical study of its kind. The company also advances directly reprogrammed endothelial cells (rECs) as next-generation vascular therapeutics in collaboration with Emory University.[1]

On its website, Karis Bio describes itself as a next-generation cell therapy company and highlights activities such as participating in BIO KOREA 2025 and engaging with global bio/pharma companies, including interest in clinical-grade iPSC supply, cell and gene therapy CDMO services, and preclinical animal testing services.[7][8] The company also posts updates and achievements through its news archive.[7]